ES2159661T3 - Utilizacion de un antagonista muscarinico para la preparacion de un medicamento para el tratamiento y control del desarrollo ocular. - Google Patents

Utilizacion de un antagonista muscarinico para la preparacion de un medicamento para el tratamiento y control del desarrollo ocular.

Info

Publication number
ES2159661T3
ES2159661T3 ES96108497T ES96108497T ES2159661T3 ES 2159661 T3 ES2159661 T3 ES 2159661T3 ES 96108497 T ES96108497 T ES 96108497T ES 96108497 T ES96108497 T ES 96108497T ES 2159661 T3 ES2159661 T3 ES 2159661T3
Authority
ES
Spain
Prior art keywords
antagonist
eye
preparation
treatment
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96108497T
Other languages
English (en)
Inventor
Alan M Laties
Richard A Stone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/522,241 external-priority patent/US5122522A/en
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Application granted granted Critical
Publication of ES2159661T3 publication Critical patent/ES2159661T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UNA COMPOSICION PARA LA INHIBICION DEL CRECIMIENTO AXIAL POSTNATAL ANORMAL DEL OJO DE UN ANIMAL EN CRECIMIENTO QUE CONSTA DE UNA CANTIDAD FARMACEUTICAMENTE EFECTIVA DE UN ANTAGONISTA FARMACOLOGICO MUSCARINICO RELATIVAMENTE SELECTIVO PARA BLOQUEAR LOS RECEPTORES COLINERGICOS EN LAS CELULAS DEL CEREBRO, TEJIDO NEURAL Y/O GANGLIOS NEURALES PERO MENOS SELECTIVO PARA BLOQUEAR LOS RECEPTORES COLINERGICOS DE LAS CELULAS DE LOS MUSCULOS LISOS EN LA PARTE FRONTAL DEL OJO, ESTANDO DICHO ANTAGONISTA PRESENTE EN UN PORTADOR O DILUYENTE ADECUADO PARA LA ADMINISTRACION OCULAR. UN ANTAGONISTA ADECUADO ES LA PIRENCEPINA. OTROS ANTAGONISTAS ADECUADOS SON LA TELENCEPINA Y EL O-METOXI-SILAHEXOCICLIO.
ES96108497T 1989-06-21 1990-06-14 Utilizacion de un antagonista muscarinico para la preparacion de un medicamento para el tratamiento y control del desarrollo ocular. Expired - Lifetime ES2159661T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36929389A 1989-06-21 1989-06-21
US07/522,241 US5122522A (en) 1989-06-21 1990-05-11 Treatment and control of ocular development

Publications (1)

Publication Number Publication Date
ES2159661T3 true ES2159661T3 (es) 2001-10-16

Family

ID=27004525

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96108497T Expired - Lifetime ES2159661T3 (es) 1989-06-21 1990-06-14 Utilizacion de un antagonista muscarinico para la preparacion de un medicamento para el tratamiento y control del desarrollo ocular.
ES94112616T Expired - Lifetime ES2136686T3 (es) 1989-06-21 1990-06-14 Tratamiento y control de desarrollo ocular con agonistas colinergicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES94112616T Expired - Lifetime ES2136686T3 (es) 1989-06-21 1990-06-14 Tratamiento y control de desarrollo ocular con agonistas colinergicos.

Country Status (10)

Country Link
US (2) US5356892A (es)
EP (1) EP0478694B1 (es)
JP (4) JP3165436B2 (es)
AT (3) ATE203666T1 (es)
CA (1) CA2058768C (es)
DE (3) DE69033775T2 (es)
DK (1) DK0737475T3 (es)
ES (2) ES2159661T3 (es)
HK (1) HK1007681A1 (es)
WO (1) WO1990015604A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
ES2159661T3 (es) * 1989-06-21 2001-10-16 Univ Pennsylvania Utilizacion de un antagonista muscarinico para la preparacion de un medicamento para el tratamiento y control del desarrollo ocular.
WO1993013777A1 (en) * 1992-01-21 1993-07-22 Merck & Co., Inc. Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
AU5312198A (en) * 1997-01-06 1998-08-03 Klaus Trier Aps Screening method
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
CA2400803A1 (en) * 2000-01-18 2001-07-26 Richard A. Stone Ocular growth and nicotinic antagonists
IL158904A0 (en) * 2001-05-25 2004-05-12 Valley Forge Pharmaceuticals Pirenzepine ophthalmic gel
ITUB20160876A1 (it) 2016-02-19 2017-08-19 Dambrosio Enzo Maria Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
ES2159661T3 (es) * 1989-06-21 2001-10-16 Univ Pennsylvania Utilizacion de un antagonista muscarinico para la preparacion de un medicamento para el tratamiento y control del desarrollo ocular.
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth

Also Published As

Publication number Publication date
ATE147626T1 (de) 1997-02-15
JP3165436B2 (ja) 2001-05-14
DE69033775T2 (de) 2001-11-15
CA2058768A1 (en) 1990-12-22
DE69033775D1 (de) 2001-09-06
JP2000204049A (ja) 2000-07-25
JP2004075695A (ja) 2004-03-11
DE69033246D1 (de) 1999-09-16
US5637604A (en) 1997-06-10
ATE203666T1 (de) 2001-08-15
DE69033246T2 (de) 1999-12-02
HK1007681A1 (en) 1999-04-23
EP0478694A4 (en) 1992-07-29
ES2136686T3 (es) 1999-12-01
DK0737475T3 (da) 2001-10-08
WO1990015604A1 (en) 1990-12-27
CA2058768C (en) 2004-08-03
ATE183085T1 (de) 1999-08-15
EP0478694B1 (en) 1997-01-15
JP2001081046A (ja) 2001-03-27
US5356892A (en) 1994-10-18
EP0478694A1 (en) 1992-04-08
DE69029734D1 (de) 1997-02-27
DE69029734T2 (de) 1997-05-28
JPH05500502A (ja) 1993-02-04
JP3461778B2 (ja) 2003-10-27

Similar Documents

Publication Publication Date Title
US6410544B1 (en) Cholinergic agents in the treatment of presbyopia
Eyssette et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis
ES2159661T3 (es) Utilizacion de un antagonista muscarinico para la preparacion de un medicamento para el tratamiento y control del desarrollo ocular.
EP0348360A3 (en) Pharmacological use of uridine in the treatment of nervous disorders
Schaeppi et al. Adrenergic innervation of cat iris sphincter
KR920702622A (ko) 안구 발육의 치료 및 조절
Girado et al. The innervation of the urethra of the female cat
Nielsen et al. Responses to noradrenaline in human subcutaneous resistance arteries are mediated by both α1‐and α2‐adrenoceptors
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
JPH08511024A (ja) 眼内圧を低下させる方法および組成物
Hurwitz et al. The effects of the sympathetic nervous system on accommodation: II. Alpha sympathetic nervous system
Bonomi et al. Outflow facility after guanethidine sulfate administration
CA2369054A1 (en) Treatment and control of ocular development
JPS6426518A (en) Remedy for hyperophthalmotony
ANDERSON et al. Suppression of decerebrate rigidity by phenytoin and chlorpromazine
Dunagan et al. Nerves originating from the cerebral ganglion of Moniliformis moniliformis (Acanthocephala)
CHRISTENSEN et al. CNS alpha2-adrenoceptor induced mydriasis in conscious rats
Flentje et al. Diurnal variations of tumor growth and its influence on cytostatic treatment
SU1666116A1 (ru) Способ лечени невралгии тройничного нерва
McKearney Individual differences in effects of tricyclic antidepressants and anticholinergic drugs on operant behavior in the squirrel monkey
Bergmann et al. Respiratory responses to brain stem stimulation
Katz et al. Herpes zoster management
Kupperman Problems in the Development of Analgesic Drugs and the Evaluation of Pain
ES484664A1 (es) Un procedimiento para la preparacion de derivados octahidro-1h-benzo 4,5 furo,3,2-e isoquinolina.
Roquebert et al. Calcium antagonism of the inhibitory effects of fentanyl on the contraction of the nictitating membrane in cats

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 737475

Country of ref document: ES